Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic PurpuraSignificance

(2015) Claudia Tersteeg et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13

(2015) B. Plaimauer et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura

(2014) Jay S. Raval et al.   AMERICAN JOURNAL OF HEMATOLOGY

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

(2012) A. Schiviz et al.   BLOOD

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

(2012) Marie Scully et al.   BRITISH JOURNAL OF HAEMATOLOGY

Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

(2011) B. PLAIMAUER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

ADAMTS13mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura

(2009) Luca A. Lotta et al.   HUMAN MUTATION

Pathogenesis of Thrombotic Microangiopathies

(2008) X. Long Zheng et al.   Annual Review of Pathology-Mechanisms of Disease